Recent research from Sweden indicates that GLP-1 receptor agonists, such as Ozempic and Wegovy, may help reduce the risk of worsening anxiety and depression among individuals with these mental health conditions. The study analyzed health data from 95,490 participants diagnosed with depression and/or anxiety who were prescribed diabetes medications between 2009 and 2022.
The findings, published in The Lancet Psychiatry, suggest that those using GLP-1 drugs experienced fewer psychiatric hospitalizations and reduced sick leave due to mental health issues compared to periods when they were not on these medications. Semaglutide, in particular, was associated with a 42% lower risk of worsening mental illness, while liraglutide showed an 18% reduction. Notably, the study found that semaglutide was linked to lower risks of worsening depression, anxiety, and substance use disorders.
Researchers used a "within-individual" design, allowing participants to serve as their own controls, which helps mitigate the influence of external factors such as age and overall health. Data from national health records enabled a comprehensive analysis of mental health outcomes, including psychiatric hospitalizations and incidents of self-harm.
Experts suggest that the benefits of GLP-1 drugs may stem from their effects on dopamine signaling and brain inflammation, which could stabilize mood and improve emotional regulation. However, caution is advised, as the study is observational and does not establish causality. Further clinical trials are necessary before GLP-1 drugs can be recommended as primary treatments for mental health disorders. The findings highlight the potential for integrated care approaches that address both metabolic and mental health issues.